{"blocks":[{"@type":"@builder.io/sdk:Element","tagName":"link","properties":{"href":"https://fonts.googleapis.com/css2?family=Geist:wght@400&display=swap","rel":"stylesheet"}},{"@type":"@builder.io/sdk:Element","tagName":"div","properties":{},"responsiveStyles":{"large":{"display":"flex","width":"448px","padding":"12px 16px","flexDirection":"column","alignItems":"flex-start","gap":"16px","borderRadius":"12px","background":"#FFF","boxShadow":"0 0 54px 0 rgba(21, 21, 24, 0.06)","margin":"20px auto","height":"344px"},"medium":{"width":"90%","maxWidth":"448px"},"small":{"width":"95%","padding":"8px 12px","fontSize":"12px"}},"children":[{"@type":"@builder.io/sdk:Element","tagName":"div","properties":{"layer-name":"ХК, холангиокарцинома;  ПО, продолжительность ответа;  ФС, функциональный статус;  ECOG, Восточная объединенная группа онкологов;  IDH, изоцитратдегидрогеназа;  ЧОО, частота объективного ответа;  ОВ, общая выживаемость;  ФД, фармакодинамика;  ВБП, выживаемость без прогрессирования;  ФК, фармакокинетика; р/сут, раз в сутки;  КЖ, качество жизни;  RECIST v1.1, Критерии оценки ответа при солидных опухолях, версия 1,1;  ВДО, время до ответа на лечение.   1. Abou-Alfa GK, et al. Lancet Oncol. 2020;21(6):796–807"},"responsiveStyles":{"large":{"alignSelf":"stretch","color":"#151518","fontFamily":"Geist","fontSize":"14px","fontStyle":"normal","fontWeight":"400","lineHeight":"140%"},"medium":{},"small":{}},"children":[{"@type":"@builder.io/sdk:Element","tagName":"span","properties":{},"responsiveStyles":{"large":{"fontFamily":"Geist, -apple-system, Roboto, Helvetica, sans-serif","fontWeight":"400","fontSize":"14px","color":"rgba(21,21,24,1)"},"medium":{},"small":{"fontSize":"12px"}},"children":[{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ХК, холангиокарцинома;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ПО, продолжительность ответа;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ФС, функциональный статус;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ECOG, Восточная объединенная группа онкологов;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"IDH, изоцитратдегидрогеназа;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ЧОО, частота объективного ответа;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ОВ, общая выживаемость;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ФД, фармакодинамика;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ВБП, выживаемость без прогрессирования;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ФК, фармакокинетика; р/сут, раз в сутки;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"КЖ, качество жизни;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"RECIST v1.1, Критерии оценки ответа при солидных опухолях,"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"версия 1,1;"}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"ВДО, время до ответа на лечение."}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"br","properties":{},"responsiveStyles":{"large":{},"medium":{},"small":{}}},{"@type":"@builder.io/sdk:Element","tagName":"span","component":{"name":"Text","options":{"text":"1. Abou-Alfa GK, et al. Lancet Oncol. 2020;21(6):796–807"}}}]}],"layerName":"ХК, холангиокарцинома;  ПО, продолжительность ответа;  ФС, функциональный статус;  ECOG, Восточная объединенная группа онкологов;  IDH, изоцитратдегидрогеназа;  ЧОО, частота объективного ответа;  ОВ, общая выживаемость;  ФД, фармакодинамика;  ВБП, выживаемость без прогрессирования;  ФК, фармакокинетика; р/сут, раз в сутки;  КЖ, качество жизни;  RECIST v1.1, Критерии оценки ответа при солидных опухолях, версия 1,1;  ВДО, время до ответа на лечение.   1. Abou-Alfa GK, et al. Lancet Oncol. 2020;21(6):796–807"}]}],"vcpImportId":"vcp-5d9db2c31e2240279d7cfd6c90abb6c1"}